Pharmaceutical research plays a decisive role in the continuing improvement in public health.
Recital 2, Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…
Opinion of Advocate General Pitruzzella delivered on 23 January 2020. Santen SAS v Directeur général de l’Institut national de la propriété Decision
Second, Regulation No 469/2009 seeks to encourage pharmaceutical research by providing for protection to supplement that conferred by the patent, the effective duration of which is reduced because of the time required to obtain an MA …
23 Jan 2020 · 62018CC0673
Opinion of Advocate General Jääskinen delivered on 10 September 2015. Seattle Genetics Inc. v Österreichisches Patentamt.Decision
In so far as concerns the objectives which the provision at issue seeks to attain, it is common ground that the SPC for medicinal products introduced by Regulation No 1768/92 and codified by Regulation No 469/2009 increases the duration of …
10 Sep 2015 · 62014CC0471
Judgment of the Court (Second Chamber) of 21 June 2018. Pfizer Ireland Pharmaceuticals, Operations Support Group v Orifarm GmbH.Decision
Thus, it is apparent from recitals 2, 4, 5 and 6 of the SPC Regulation that the continuing improvement in public health through research is the main concern of the EU legislature. In the same vein, Regulation No 1901/2006 aims, according …
21 Jun 2018 · 62016CJ0681